

Anti-DLL3-PBD(Dar2)[Rovalpituzumab tesirine]

Product Information


Product Name	Anti-DLL3-PBD(Dar2)[Rovalpituzumab tesirine]
Storage temp.	Store at +4°C short term. Store at -80°C for 36 months, avoiding freeze/thaw cycles.
Catalog# / Size	GM-87847AB-100 / 100 µg GM-87847AB-1mg / 1 mg

Antibody Information

Expression System	CHO
Purity	> 95% as determined by SDS-PAGE
Aggregation	< 5% as determined by SEC-HPLC
Drug-to-Antibody Ratio (DAR)	1.0-2.0
Endotoxin	<1EU/mg
Sterility	0.22 µm Filtered
Target	DLL3
Clone	Rovalpituzumab tesirine
Alternative Names	SCDO1
Source/Isotype	Monoclonal Human IgG1 (Delta 447K), kappa
Application	Positive control of Cytotoxicity Assay
Description	Rovalpituzumab tesirine (Rova-T) is an antibody-drug conjugate (ADC) designed specifically to target diseases with high expression of DLL3 (Delta-like ligand 3), with a particular focus on small cell lung cancer (SCLC). The mechanism of action of Rova-T combines the high specificity of the antibody with the potent cytotoxicity of its payload. By targeting DLL3 on the surface of tumor cells, Rova-T delivers its anticancer drug payload directly into these cells. Once Rova-T binds to DLL3 and is internalized by the tumor cell, the toxic payload (such as tesirine) is released, where it attaches to and damages the tumor cell's DNA, causing double-strand breaks and ultimately triggering cell death. This design enables precise destruction of tumor cells while minimizing toxicity to normal tissues.
Formulation	20 mM Histidine, 100 mM NaCl, pH 6.0


Version:3.1

SDS-PAGE





On SDS-PAGE under reducing (R)/non-reducing(N-R) condition. The purity of the protein is greater than 95%.

SEC-HPLC



The purity of this product is greater than 95% verified by SEC-HPLC.

HIC-HPLC



The drug-to-antibody ratio (DAR) of this product is 1.82